Sun Pharma gets China NMPA approval for ILUMETRI to treat moderate-to-severe plaque psoriasis
Express Pharma
MAY 30, 2023
Sun Pharmaceutical Industries announced that the New Drug Application (NDA) for tildrakizumab injection under the brand name ILUMETRI has been approved by the National Medical Products Administration of the People’s Republic of China (NMPA).
Let's personalize your content